Abstract
The present work was aimed that in vitro antioxidant activity of some novel synthetic mononuclear Ruthenium (II) compounds namely, Ru (1, 10-phenanthroline)2(2-nitro Phenyl thiosemicarbazone)Cl2 (compound R1) and Ru (1, 10- phenanthroline)2(2-hydroxy-phenyl thiosemicarbazone)Cl2 (compound R2) using [2, 29-azinobis-(3-ethylbenzothiazoline- 6-sulfonic acid)] (ABTS), Ferric reducing antioxidant power (FRAP), N, N-dimethyl-p-phenylenediamine (DMPD), 1, 1- diphenyl-2-picryl hydrazine (DPPH) and Nitro blue tetrazolium (NBT) assays. The results concluded that both the compounds (R1&R2) exhibited a significant antioxidant activity. But compared to reference standards, R1 was found to be better free radical scavenging activity than R2.
Keywords: Antioxidant, ABTS, DMPD, DPPH, FRAP, NBT, Ruthenium compounds
Letters in Drug Design & Discovery
Title:In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium (II) Compounds
Volume: 9 Issue: 4
Author(s): Shyam Sunder Anchuri, Sreekanth Thota, Rajeshwar Yerra, Satyavati Dhulipala
Affiliation:
Keywords: Antioxidant, ABTS, DMPD, DPPH, FRAP, NBT, Ruthenium compounds
Abstract: The present work was aimed that in vitro antioxidant activity of some novel synthetic mononuclear Ruthenium (II) compounds namely, Ru (1, 10-phenanthroline)2(2-nitro Phenyl thiosemicarbazone)Cl2 (compound R1) and Ru (1, 10- phenanthroline)2(2-hydroxy-phenyl thiosemicarbazone)Cl2 (compound R2) using [2, 29-azinobis-(3-ethylbenzothiazoline- 6-sulfonic acid)] (ABTS), Ferric reducing antioxidant power (FRAP), N, N-dimethyl-p-phenylenediamine (DMPD), 1, 1- diphenyl-2-picryl hydrazine (DPPH) and Nitro blue tetrazolium (NBT) assays. The results concluded that both the compounds (R1&R2) exhibited a significant antioxidant activity. But compared to reference standards, R1 was found to be better free radical scavenging activity than R2.
Export Options
About this article
Cite this article as:
Shyam Sunder Anchuri, Sreekanth Thota, Rajeshwar Yerra, Satyavati Dhulipala , In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium (II) Compounds, Letters in Drug Design & Discovery 2012; 9 (4) . https://dx.doi.org/10.2174/157018012799859927
DOI https://dx.doi.org/10.2174/157018012799859927 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genomic Instability and Carcinogenesis: An Update
Current Genomics Transcription, DNA Damage and Beyond: The Roles of Histone Ubiquitination and Deubiquitination
Current Protein & Peptide Science Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy Computer-Aided Drug Design for Cancer-Causing H-Ras p21 Mutant Protein
Letters in Drug Design & Discovery Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry Targetting Esophageal and Gastric Cancers with Monoclonal Antibodies
Current Topics in Medicinal Chemistry Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets The Evolution of Clostridium difficile Infection in Cancer Patients: Epidemiology, Pathophysiology, and Guidelines for Prevention and Management
Recent Patents on Anti-Infective Drug Discovery Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes
Current Drug Targets Irreversible Protein Kinase Inhibitors
Current Medicinal Chemistry Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry